Funding for this research was provided by:
University of Gothenburg
Received: 30 May 2022
Accepted: 15 November 2022
First Online: 24 November 2022
: The study was approved by the National and Regional Ethics Committee in Sweden and the University of Gothenburg. For the teriparatide -study: D-number 2004: M-004 approved in 2004, D-number 2006: 098 approved in 2006 and D-number 1142–18/2019–00738 approved in 2019; for the growth hormone-study: D-number 386–92 approved in 1993, D-number 543–00 approved in 2001 and D-number 2019–05675 approved in 2020; and for the WHO MONICA project Gothenburg: D-number 244–94 approved in 1994, D-number 088–06 approved in 2006 and D-number T282–11 approved in 2011. All participants gave their written informed consent. The Declaration of Helsinki was followed.
: Not applicable.
: The authors declare that they have no competing interests in this section.